 Home > Active Ingredient News > Antitumor Therapy > JCO: HER2 expression in metastatic gastric cancer and its impact on survival

JCO: HER2 expression in metastatic gastric cancer and its impact on survival

 Last Update: 2021-04-13
 Source: Internet
 Author: User

Tags

blood test alzheimer's

test osteoarthritis

Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

Trastuzumab is the only targeted drug approved for the treatment of human epidermal growth factor receptor 2 positive (HER2+) metastatic gastric cancer (mGC).

Stomach cancer

The study conducted a prospective multicenter study to determine the resistance mechanism of mGC patients to HER2 targeted therapy.

Figure 1 Screenshot of the paper publication page

It is estimated that gastric cancer is the fifth most common malignant tumor in the world, with more than 1 million new cases every year and a high mortality rate.

The study recruited patients receiving mGC treatment to 35 German research centers with a follow-up period of up to 48 months.

Figure 2 Technical route

The HER2 status was assessed intensively by immunohistochemistry and chromogenic in situ hybridization, and the expression of HER2 gene was detected by quantitative PCR.

immunity

The study did not establish a detailed statistical analysis plan, but made a rough estimate of the expected number of cases observed.

In the management of patients receiving trastuzumab combined with chemotherapy, patients with HER2 + mGC (HER2+/HER2 +, n=60) confirmed by the center had significantly longer OS than HER2-/HER2+ receiving trastuzumab combined with chemotherapy Patients tested (n = 65).

Figure 3 Center HER2 test results

The study found that significant differences in HER2 evaluation of mGC were found in tumor specimens with moderate HER2 expression.

The degree of HER2 positivity and the heterogeneity of HER2 expression should be resistance factors for HER2 targeted therapy in mGC patients

references:

Haffner I, Schierle K, Raimúndez E, Geier B, Maier D, Hasenauer J, Luber B, Walch A, Kolbe K, Riera Knorrenschild J, Kretzschmar A, Rau B, Fischer von Weikersthal L, Ahlborn M, Siegler G, Fuxius S , Decker T, Wittekind C, Lordick F.

org/doi/abs/10.
1200/JCO.
20.
02761">https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761org/doi/abs/10.
1200/JCO.
20.
02761"> https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761 https://ascopubs.
org/doi/abs/10.
1200/JCO.
20.
02761Leave a message here

This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.